Logo

Cellular Re-programming utilizing the Immune system​

We use immune cells to deliver protein directly to the cytoplasm of diseased cells to improve patient health and longevity.

Cellular Re-programming utilizing the Immune system​

We use immune cells to deliver protein directly to the cytoplasm of diseased cells to improve patient health and longevity.

It all starts inside the cell...

1

2/3 of all proteins are inside our cells, including many key targets for disease pathways

2

Very few technologies are able to target specific tissues or specific cellular compartments. Edity can do both

3

Many potential classes of theraputics protein (beyond antibodies) are fundamentally limited by current delivery technologies

4

Immune cells can achieve deep tissue penetrance and can also recognize inflammatory signals from the body

5

Limits around tissue tropism, toxicity and payload size are major barriers in treating patients. Immune cells overcome these issues

In nature, immune cells deliver a toxic payload to eliminate diseased cells

WE REDESIGN THE IMMUNE CELLS TO DELIVER PROTEIN THERAPEUTICS INSTEAD

This opens up a new universe of targets for treatment that have not previously been translated to the clinic

We deliver proteins to cells anywhere in the body

Creating new modalities for intracellular therapy

ABOUT US

Edity is developing an exciting new platform that harnesses the immune system to deliver therapeutic proteins direct to the cytoplasm of target cells to reprogram cells and tissue back to health.

The technology creates the opportunity to change the course of disease at the intracellular level via multiple mechanisms including protein replacement, target modulation, genetic correction and protein gain of function.  Currently, the company is working across a number of indications, including oncology and genetic disease, while developing programs for regeneration and longevity.

Our People

Eyal is a serial entrepreneur and has devoted the majority of his career to building medical device companies. He founded TopSpin medical, Pi-Cardia and Clear-Cut.

Eyal Kolka​

CO-FOUNDER, CHAIRMAN OF THE BOARD​

Michal is graduate of the Weizmann Institute of Science and a seasoned expert in gene editing and genetic screening, having spent four years at Emendo before going onto found her own company, Applied Genetics. Michal founded Edity in 2020.

Michal Golan-Mashiach
PhD, MBA

CO-FOUNDER AND CEO

Brian is a veteran of the gene editing field, having started with ZFNs before moving on to CRISPR and base editing at Horizon Discovery. He was instrumental in the sale of Horizon to PerkinElmer for $383M.

Brian Burke, PhD

CBO

Ofer is an expert in tumor immunology and has gained a strong industrial experience in Compugen focusing on target validation of immuno-oncology programmes.

Ofer Levy, PhD

VP R&D

Sharon is an experienced biochemist and renowned oligo nucleotides expert. At QBI, she headed the entire planning of pre-clinical studies the pre-clinical siRNA pipeline, including in vitro and in vivo trials.

Sharon Avkin Nachum, PhD​

VP TECHNOLOGY 

Assaf is an expert in CAR-T science and has had positions at the Weizmann Institute, UC Berkely and AbbVie. He is an inventor on one of the first allogeneic CAR T cell patents.

Assaf Marcus, PhD

VP TRANSLATIONAL SCIENCE

Scientific Advisors

Chair of Pediatrics at Columbia University. An international leader in immunobiology of human NK cells.

Jordan S. Orange

Columbia University

American Cancer Society Professor and Chair of the Department of Microbiology and Immunology, UCSF. An internationally-recognized expert in natural killer (NK) cells.

Lewis Lanier

UCSF

Scientific director at Leibniz Research Centre, Technical University Dortmund. Investigates the immunological and molecular process of NK cell recognition

Carsten Watzl

Technical University Dortmund

One of the pioneers of the world’s first CAR-T technologies. Founder of IMMPACT-Bio and GentiBio

Gideon Gross

IMPACT BIO

A world leader in the research of immunotherapies directed at targeting the intracellular proteome at the Technion

Yoram Reiter

Technion

Investors

CONTACT US

+972-54-7414417
info@edity-tx.com
10 Menachem Plaut St.
7670609, Rehovot, IL